“Clinical benefit” following treatment with antineoplastic drugs: What does it mean and how should we measure it? Maurie Markman Editor’s Commentary Pages: 1 - 2
The biology of human epidermal growth factor receptor 2 Srividya SundaresanElicia PenuelMark X. Sliwkowski OriginalPaper Pages: 16 - 22
Dose-intensive chemotherapy for locally advanced breast cancer Jolanda G. SchramaSjoerd Rodenhuis OriginalPaper Pages: 23 - 30
New data on adjuvant therapy for breast cancer Antonio C. WolffNancy E. Davidson OriginalPaper Pages: 31 - 37
Concurrent chemotherapy and radiation therapy in primary cancer of the cervix Jeanne M. SchilderFrederick B. Stehman OriginalPaper Pages: 41 - 46
Systemic therapy for advanced or recurrent endometrial carcinoma Gini F. Fleming OriginalPaper Pages: 47 - 53
Dose-intensive approaches to ovarian cancer Nicholas LambrouEdward L. Trimble OriginalPaper Pages: 54 - 58
Vascular endothelial growth factor in ovarian cancer Darcie A. HazeltonThomas C. Hamilton OriginalPaper Pages: 59 - 63
The roles of second-look laparotomy and cancer antigen 125 in the management of ovarian carcinoma Alberto E. SelmanLarry J. Copeland OriginalPaper Pages: 71 - 76
In vitro chemosensitivity testing and mechanisms of drug resistance Krishnansu TewariAlberto Manetta OriginalPaper Pages: 77 - 84